Gallium-68 NY 108 - Norroy Bioscience
Alternative Names: 68Ga-NYM-032; 68Ga-NYM032 PET/CT; Gallium-68 NY-108; Gallium-68 NY108 PET/CT; Gallium-68 NYM 032Latest Information Update: 05 Sep 2024
At a glance
- Originator Norroy Bioscience
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 05 Sep 2024 Phase-I/II clinical trials in Prostate cancer (Diagnosis) in China (IV) prior to September 2024 (Norroy Bioscience Pipeline, September 2024)
- 24 Apr 2024 Phase-I clinical trials in Prostate cancer (Diagnosis) in China (IV) (NCT06389695)
- 11 Feb 2024 US FDA approves IND application for Gallium-68 NY 108 in Prostate cancer